Literature DB >> 7659445

Octreotide in the treatment of diarrhoea induced by coeliac plexus block.

Sebastiano Mercadante1.   

Abstract

Prolonged and severe diarrhoea after alcohol celiac plexus block is a rare, but life-threatening, complication if not recognized. This type of diarrhoea may be considered an autonomic neuropathy due to sympathetic denervation. A 65-year-old pancreatic cancer patient developed serious diarrhoea after celiac plexus block which was unresponsive to traditional treatment such as loperamide, dyphenoxylate and opioids. Subcutaneous octreotide, 0.1 mg twice a day, achieved a complete resolution of the symptom. This drug was maintained at the same dosage and was well tolerated for 4 months until death. Octreotide, an analogue of somatostatin, reduces diarrhoea by suppression of intestinal motility and secretion and offers a useful option in the treatment of this complication of celiac plexus block.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659445     DOI: 10.1016/0304-3959(94)00267-I

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

Review 1.  Celiac block for the treatment of pancreatic pain.

Authors:  S Ischia; E Polati; G Finco; L Gottin
Journal:  Curr Rev Pain       Date:  2000

2.  Bilateral thoracoscopic splanchnicectomy in chronic intestinal pseudo-obstruction: report of two paediatric cases.

Authors:  K Khelif; M Scaillon; M J M Govaerts; J M Vanderwinden; M H De Laet
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

Review 3.  Endoscopic ultrasonography guided celiac plexus neurolysis and celiac plexus block in the management of pain due to pancreatic cancer and chronic pancreatitis.

Authors:  Anthony J Michaels; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

Review 4.  Established and potential therapeutic applications of octreotide in palliative care.

Authors:  Eric E Prommer
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.